Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The general objectives are to evaluate the pre-operative activity and the safety of afatinib
in head and neck cancer and to explore the different downstream molecular pathways to
identify tumor response and resistance mechanisms. The results from this study can be used to
conduct a larger trial that would allow us to confirm or validate the hypotheses generated.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC